NCT01625351 2026-02-06
A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas
St. Jude Children's Research Hospital
Phase 1 Completed
Clinical Trials
12 trialsNCT03989466 2024-10-10
Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00057005 2020-01-18
ADVL
Baylor College of Medicine
Phase 1 Completed
NCT03132584 2019-01-14
Cyclophosphamide and Alemtuzumab In Lymphoma
Dana-Farber Cancer Institute
Phase 1 Terminated
NCT00323323 2017-01-20
CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT00104975 2016-12-15
Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
Yale University
Phase 1 Completed
NCT00637390 2016-12-02
A Phase I Study of Alemtuzumab in Patients With Relapsed Ovarian/Primary Peritoneal Cancer.
University of Michigan Rogel Cancer Center
Phase 1 Terminated
NCT00330252 2016-05-13
Weekly Subcutaneous Alemtuzumab and Rituximab for Relapsed CLL
Dana-Farber Cancer Institute
Phase 1 Completed
NCT00943293 2014-03-17
Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies
University of Chicago
Phase 1 Terminated
NCT00947388 2013-08-22
Bendamustine Plus Alemtuzumab for Refractory Chronic Lymphocytic Leukemia (CLL)
Case Comprehensive Cancer Center
Phase 1 Terminated
NCT00458250 2008-11-18
Feasibility of Haploidentical Hematopoietic Stem Cell Transplantation Using CAMPATH-1H
Tehran University of Medical Sciences
Phase 1 Completed
NCT00161590 2008-10-22
Study of CHOP + Campath for T-Cell, Null Cell, or Natural Killer (NK)-Cell Lymphoma
Weill Medical College of Cornell University
Phase 1 Completed